Personalities

Nataliya N. Babyshkina

Nataliya N. Babyshkina, MD, PhD, Senior Researcher Department of Experimental Oncology, Laboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

Contact details

e-mail: nbabyshkina@mail.ru
tel.: +7 3822 282676 ext 3340
fax: +7 (3822) 51-40-97

ResearchGate: https://www.researchgate.net/profile/Nataliya_Babyshkina

РИНЦ: SPIN-код: 2738-9275, AuthorID: 183828

ResearcherID Web of Science: A-7526-2012

Scopus (Author ID): 26641099700

ORCID: https://orcid.org/0000-0002-0562-3878

Brief Biography

2019 - D.Sc. (Medical Sciences), Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science

2005 – Ph.D. Degree (Medical Sciences), Oncology, Physiopathology, Cancer Research Institute, Tomsk, Russia

1990-1996 – Medical Doctor-Biochemist Honors Diploma, Siberian State Medical University, Tomsk, Russia

2013-present day – Senior Researcher. Dept.of Experimental Oncology, Laboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center

2010-2013 – Research Fellow. Dept.of Experimental Oncology, Cancer Research Institute, Tomsk, Russia

2009-2010 – Scientist. Dept.of Therapeutic Radiology and Oncology, Laboratory for Translational Research in Radiooncology, Innsbruck Medical University, Austria

2007-2009 – Research Fellow. Dept.of Experimental Oncology, Cancer Research Institute, Tomsk, Russia

2000-2007 – Junior Scientist. Dept.of Experimental Oncology, Cancer Research Institute, Tomsk, Russia

1996-2000 – Staff Scientist. Clinical Laboratory Immunology, Cancer Research Institute, Tomsk, Russia

1990-1996 – Student of biochemistry medicine. Medical Biology Faculty, Siberian State Medical University, Tomsk, Russia

Research Interests

Dr. Babyshkina's major research interests focused on molecular mechanisms that regulate cancer cell proliferation, survival and dissemination to identify critical components of these pathways as targets for novel cancer therapies.

Her current research project includes comprehensive molecu­lar characterization of luminal and triple-negative subtype to examine the prognostic and predictive value of informative markers associated with PI3-K⁄Akt pathway which could be useful to individualize endocrine therapy or neoadjuvant chemotherapy for breast cancer subtypes.

Her other research interests are focused on the study of the gene expression profile that predicts the response to chemotherapy in metastatic colorectal cancers to explore the possible mechanisms involved in chemotherapy resistance.

Achievements, awards, and grants 

Regional Foundation of Assistance to Russian medicine, Russian Academy of Medical Sciences Individual Grant (2008)

Financial assistance of WCBCF (World Conference on Breast Cancer Foundation) (2008)

Travel grant of the IMPAKT Breast Cancer Conference Secretariat (2009)

Fellowship grant of the EBCC-7 Organizing Committee (2010)

Travel grant of the EORTC-NCI-AACR Organizing Committee (2010)

Travel grant of the 11^th International Breast Cancer Conference in St.Gallen (2011)

Cureline, Inc, South San Francisco, CA grant to attend AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, San Francisco, USA and research in Cureline Tissue Bank (2011)

Cureline/AACR grant to attend The American Association for Cancer Research Annual Meeting, San Diego, CA, USA (2014)

Cureline, Inc, South San Francisco, CA grant to attend the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Boston, MA. Philadelphia (2015)

Main Publication

1.      Dronova T.A., Babyshkina N.N., Matvienko N.V. et al. PI3K/Akt/mTOR: contribution to the tumor phenotype sensitive to tamoxifen. Russian Journal of Biotherapy. 2021;20(1):16–23. (In Russ.). Doi:10.17650/1726-9784-2021-20-1-16-23

2.      Dronova T A,  Babyshkina N N,  Zavyalova M V ,  Slonimskaya E M,  Cherdyntseva N V. (2021) Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients. Mol Biol. 55(1):118-125. doi: 10.31857/S0026898421010055.

3.      Gervas P, Molokov A, Schegoleva A, Kiselev A, Babyshkina N, Pisareva L, TyukalovY, Choynzonov E, Cherdyntseva N. (2020) New germline mutations in non-BRCA genes among breast cancer women of mongoloid origin. Molecular Biology Reports. 47(7): 5315-5321. doi: 10.1007/s11033-020-05612-2.

4.      Babyshkina N.N., Dronova T.A., Zambalova E.A., Zavyalova M.V., Slonimskaya E.M., Cherdyntseva N.V. The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients. Bulletin of Siberian Medicine. 2020; 19 (1): 13–20. https://doi.org: 10.20538/1682-0363-2020-1-13–20.

5.      Erdyneeva D.B., Babyshkina N.N., Dronova T.A., Vtorushin S.V., Slonimskaya E.M., Stegniy V.N., Cherdyntseva N.V. ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE. Siberian journal of oncology. 2020;19(4):138-145. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-4-138-145

6.      Babyshkina N, Vtorushin S, Dronova T, Patalyak S, Slonimskaya E, Kzhyshkowska J, Cherdyntseva N, Choynzonov E.(2019) Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. Clin Exp Med. 2019 Nov;19(4):547-556.  DOI: 10.1007/s10238-019-00583-6.

7.      Dronova T.A., Babyshkina N.N., Zavyalova M.V. et al. Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer. Advances in Molecular Oncology 2018;5(3):40–50.https://doi.org/10.17650/2313-805X-2018-5-3-40-50.

8.      Babyshkina N, Zavyalova M, Tarabanovskaya N, Dronova T, Krakhmal N, Slonimskaya E, Kzhyshkowska J, Choynzonov E, Cherdyntseva N. (2018) Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem. 444(1-2):197-206. doi: 10.1007/s11010-017-3244-1.

1. N. Babyshkina, M. Zavyalova, S. Patalyak, T. Dronova, E. Slonimskaya, and N. Cherdyntseva. (2017) Non-Smad TGF-β signaling components are possible biomarkers of tamoxifen resistance. AIP Conference Proceedings 1882, 020003. doi: 10.1063/1.5001582
2. Babyshkina N, Vtorushin S, Zavyalova M, Patalyak S, Dronova T, Litviakov N, Slonimskaya E, Kzhyshkowska J, Cherdyntseva N, Choynzonov E. (2017) The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clin Exp Med. Aug;17(3):383-393. doi: 10.1007/s10238-016-0428-z.
3. Babyshkina N.N., Zavyalova M.V., Bragina O.D., Dronova T.A., Slonimskaya E.M., Cherdyntseva N.V. Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients. Siberian journal of oncology. 2016;15(5):9-17. (In Russ.) DOI:10.21294/1814-4861-2016-15-5-9-17
4. N. Babyshkina, S. Vtorushin, S. Patalyak, T. Dronova, E. Slonimskaya, N.Cherdyntseva. Prognostic significance of immunohistochemical and genetic markers in Russian breast cancer patients treated with adjuvant tamoxifen (2015) Proceeding of EJC SUPPLEMENTS, 13: 2-3. http://dx.doi.org/10.1016/j.ejcsup.2015.08.003
5. Nataliya Babyshkina, Sergey Vtorushin, Stanislav Patalyak, Tatyana Dronova, Elena Slonimskaya, Nadejda Cherdyntseva. The distribution pattern of ERα expression, VEGFR2 expression level and its genetic variation as potential biomarkers for tamoxifen resistance (2015) Proceedings of Mol Cancer Ther 14(12) Suppl 2. DOI: 10.1158/1535-7163.TARG-15-A26
6. Babyshkina N, Malinovskaya E, Patalyak S, Bragina O, Tarabanovskaya N, Doroshenko A, Slonimskaya E, Perelmuter V, Cherdyntseva N. (2014) Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Medical Oncology. Sep;31(9):165.
7. Slonimskaya E.M., Vtorushin S.V., Babyshkina N.N., Patalyak S.V. (2014) Role of morphologicaland genetic structural characteristics of estrogen receptor alpha in the development of resistance to endocrinotherapy with tamoxifen in patients with luminal breast cancer. Siberian Journal of Oncology. 3:39-44.
8. Patalyak S.V., Slonimskaya E.M., Vtorushin S.V., Babyshkina N.N., Perelmuter V.M., Zavyalova M.V., Churilova L.A., Bakharev S.Yu. (2014) Influence of distribution pattern of ERα and their individual genetic features on efficiency of tamoxifen treatment in luminal breast cancer patients. Postgraduate doctor journal. 62(1.3): 423-427.
9. Babyshkina N, Malinovskaya E, Nazarenko M, Koval M, Gervas P, Potapova O, Slonimskaya E, Cherdyntseva N. (2013) The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients. Gene. 518:397-404.
10. Shevchenko A.V, Konenkov V.I, Babyshkina N.N, Savenkova О.V, Slonimskaya E.M. (2013) Analysis of associations of VEGF-A gene polymorphism at positions 2578A/C and +936C/T with different receptor status in breast cancer patients. Siberian Journal of Oncology.1:32-37.
11. Kukharev Y.V, Stakheeva M.N, Doroshenko A.V, Litvyakov N.V, Babyshkina N.N, Slonimskaya E.M, Cherdyntseva N.V. (2013) Relationship of the immunological parameters with neoadjuvant chemotherapy effectiveness in breast cancer patients. Siberian Journal of Oncology.2:50-57.
12. Denisov E.V., Cherdyntseva N.V., Litvyakov N.V., Malinovskaya E.A., Babyshkina N.N., Belyavskaya V.M., Voevoda M.I. (2012) TP53 gene polymorphisms in cancer risk: The modulating effect of ageing, ethnicity and TP53 somatic abnormalities. Tumor Suppressor Genes. P.Y. Cheng (ed), (InTech).Rijeka, Croatia, 79-110.
13. Cherdyntseva NV, Denisov EV, Litviakov NV, Maksimov VN, Malinovskaya EA, Babyshkina NN, Slonimskaya EM, Voevoda MI, Choinzonov EL. (2012) Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. DNA Cell Biol. 31:306-16.
14. Babyshkina N.N, Malinovskaya E.A, Stakheyeva M.N, Volkomorov V.V, Cherdyntseva N.V, Slonimskaya E.M. (2011) Association of functional polymorphism in the TGFβ1-509C>T gene with infiltrating ductal breast carcinoma risk in a Russian population. Cancer Epidemiol. 35 560–563.
15. Babyshkina N.N, Malinovskaya E.A, Zavyalova M.V, Cherdyntseva N.V, Slonimskaya E.M. (2011) Molecular breast cancer subtypes: relationship with clinicopathological characteristics, efficacy of neoadjuvant chemotherapy and survival // The Breast Supplement 1. S41.
16. Babyshkina N.N, Malinovskaya E.A, Stakheyeva M.N, Volkomorov V.V, Ufandeev A.A., Slonimskaya E.M. (2010) Role of the transforming growth factor-beta1 in breast cancer pathogenesis. Siberian Oncology Journal 6: 63-70.
17. Babyshkina N.N, Gulyaeva L.F, Malinovskaya E.A, Ivanova A.A, Cherdyntseva N.V, Slonimskaya E.M. (2010) Genetic polymorphisms of transforming growth factor-beta1 and estrogen metabolizing enzyme in estrogen receptor-positive and -negative infiltrating ductal breast carcinoma. Proceeding of European Journal of Cancer Supplements, 8(7): 197.
18. Babyshkina N.N, Gulyaeva L.F, Malinovskaya E.A, Stakheyeva M.N, Cherdyntseva N.V, Slonimskaya E.M. (2010) Estrogen metabolism genes and transforming growth factor beta1 gene polymorphisms in estrogen receptor-positive and –negative infiltrating ductal breast carcinoma. Proceeding of Annals of Oncology, 21(4): 54.
19. Babyshkina N.N, Shevchenko A.V, Salakhutdinova M.Yu, Maximov V.N, Cherdyntseva N.V, Slonimskaya E.M. (2010) The prognostic value of angiogenesis genes polymorphisms in women with infiltrating ductal breast carcinoma. Proceeding of European Journal of Cancer Supplements, 8(34): 108.
20. Babyshkina N.N, Maximov V.N, Voevoda M.I, Salakhutdinova M.Yu, Konenkov V.I, Malinovskaya E.A, Stakheyeva M.N, Cherdyntseva N.V, Slonimskaya E.M. (2009) Association of polymorphisms of angiogenesis genes with infiltrating ductal breast carcinoma. Tomsk Region and Taiwan: Experience of Scientific – Technical and Innovation Cooperation. Proceeding of Siberian-Taiwan Forum 16-17 September, Tomsk pp. 97-99.
21. Babyshkina N.N, Malinovskaya E.A, Stakheyeva M.N, Cherdyntseva N.V, Slonimskaya E.M. (2009) Association of TP53 (Arg72Pro), CCR5 (del32) and TGFB1- 509C>T gene polymorphism and their combinations with breast cancer risk and pathologic response after neoadjuvant chemotherapy. Proceeding of Annals of Oncology, 20(2): 1139.=
22. Gervas P.A., Litvyakov N.V, Stakheyeva M.N, Miller S.V., Dobrodeev A.Yu., Garbukov E.Yu, Babyshkina N.N., Kukharev Ya.V, Vasilyeva M.V., Slonimskaya E.M., Belyavskya V.A., Tuzikov S.A., Cherdyntseva N.V. (2009) Influence of apoptosis genes polymorphism and DNA repair genes on the efficacy neoadjuvant chemotherapy in cancer. Siberian Journal of Oncology, (4):41-47.
23. Silkov A.N., Goreva Е.P., Jovmer А.S., Kireev F.D., Maksimov V.N., Pilipenko I.V., Мalinovskaya Е.А., Babyshkina N.N., Litvyakov N.V. , Sennikov S.V., Коzlov V.А. (2009) Polymorphisms genes IL-18 and IL-1β in patients with breast cancer. Russian Journal of Immunology, (3):259-266.
24. Babyshkina N., Shevchenko A., Cherdyntseva N., Slonimskaya E. (2009) TGFB1– 509C>T and IL10–92C>A polymorphic variants in relationship to breast cancer progression and response to neoadjuvant chemotherapy. Proceeding of European Journal of Cancer, 7(4): 11-12.
25. Perelmuter V.M, Zavyalova M.V, Vtorushin S.V, Slonimskaya E.M, Kritskay N.G, Garbukov E.Yu, Litvyakov N.V, Stakheyeva M.N, Babyshkina N.N, Malinovskaya E.A, Denisov E.V, Lebedev I.N, Nazarenko M.S, Sennikov S.V, Goreva E.P, Kozlov V.A, Voevoda M.I, Maksimov V.N, Belyavskya V.A, Cherdyntseva N.V. (2008) Genetic and clinicopathologic characteristics in premenopausal and menopausal breast cancer patients. Progress gerontology 4: 643-654.
26. Stakheyeva M.N, Kukharev Ya.V, Garbukov E.Yu, Litvyakov N.V, Babyshkina N.N, Medyuhina A.A, Doroshenko A.V, Kokorina Yu.L, Kologrivova E.N, Slonimskaya E.M, Cherdyntseva N.V. (2008) Studying relations of immune system with the efficacy of neoadjuvant chemotherapy in mammary cancer patients. Siberian Medical Journal 3: 39-43.
27. Cherdyntseva N.V, Slonimskaya E.M, Belyavskya V.A, Babyshkina N.N, Smetannikova N.A, Gervas P.A, Denisov E.V, Stakheyeva M.N, Garbukov E.Yu, Malinovskaya E.A, Litvyakov N.V, Voevoda M.I. (2007) An association of polymorphism in the oncosuppressor P53 and the chemokine receptor CCR5 genes and their combinations with a risk for breast cancer development and progression Molecular Medicine 1: 23-31.
28. Babyshkina N.N, Stakheyeva M.N, Slonimskaya E.M, Cherdyntseva N.V, Garbukov E.Yu. (2006) Immunological parameters and cytokine production level in patients with proliferative diseases and breast cancer. Cytokines and Inflammation. 5(1): 36-43.